Intra‐arterial infusion of 5‐fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder*

Awakura, Yasuhiro; Yamamoto, Masakazu; Fukuzawa, Shigeki; Nonomura, M; T, Fukuyama

doi:10.1046/j.1442-2042.1999.611106.x

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[21][22][23] These lesions share similarities with other adenocarcinomas; hence, the suggestion of chemotherapy regimens such as platinum-based therapy like the 5-FU, leucovorin, and cisplatin combination are commonly used in colonic adenocarcinomas. 24,25 Several other cancers especially those of genitourinary origins such as bladder cancer and primary urethral cancers are also known to have similar chemotherapeutic treatments as urethral diverticular cancers based on extrapolated evidence, hence the role of various other chemotherapeutic combinations that have been shown to have benefits, for example, gemcitabine /cisplatin (GC) combination and methotrexate/doxorubicin /vincristine/cisplatin (MVAC) combination. 26 The difference in histologic types has also been seen to vary based on what part of the diverticular the tumor originates from and based on immunoreactivity with carcinoembryonic antigen and prostatespecific antigen.…”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Advanced Urethral Diverticular Adenocarcinoma and a Review of Treatment Modalities

Oluyadi

Ramachandran

Gotlieb

2019

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

Female urethral diverticular cancer is a very rare entity with only around 100 cases reported so far in literature and accounts for <1% of all malignancies. In this article, we present a 47-year-old African American female with repeated hospital visits for urinary retention, hematuria, and urinary tract infections. Initial computed tomography imaging and cystoscopy was unremarkable except for a distended urinary bladder. Subsequent magnetic resonance imaging and corresponding cystoscopy eventually indicated the presence of a urethral diverticulum. She underwent urethral diverticulectomy and was found to have a mass arising from urethral diverticulum extending to vaginal walls. Her biopsy was suggestive of invasive adenocarcinoma in advanced stages, for which she subsequently underwent a total pelvic exenteration. Next-generation sequencing of the tumor showed CDKN2A/B loss, MSI-stable, and low TMB, thereby ruling out the options for targeted therapies. Extensive literature search and expert opinions were sought for her case since no consensus exists regarding the optimal therapeutic approach due to the rarity of this tumor. A final decision was made to treat her with platinum-based chemotherapy. Different treatment approaches including neoadjuvant chemoradiation followed by surgery, surgery followed by adjuvant chemotherapy, and surgery followed by chemoradiation have been tried. Platinum-based chemotherapy has generally been preferred based on an extensive literature search. Multimodality treatment approach seems to be the current approach to management for advanced stages for better overall survival. This case illustrates the challenges faced in making diagnosis and treatment decisions due to the rarity of this type of tumor and lack of consensus in the treatment approach.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Case of Advanced Urethral Diverticular Adenocarcinoma and a Review of Treatment Modalities

Oluyadi

Ramachandran

Gotlieb

2019

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

show abstract

“…The combination of 5‐FU/CDDP or LV has been used in gastrointestinal adenocarcinoma 16,17 . We have previously reported a case of primary bladder adenocarcinoma which showed pathological complete response to intra‐arterial infusion of 5‐FU, CDDP and LV 18 . This combination may be useful to achieve the local control of urethral diverticular adenocarcinoma and allow for a bladder‐sparing approach with a successful outcome.…”

Section: Discussionmentioning

confidence: 99%

Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy

et al. 2003

Self Cite

View full text Add to dashboard Cite

A 75-year-old female presented with a 7-month history of intermittent macrohematuria and urinary retention. Physical examination revealed a firm, round mass on the anterior vaginal wall. The diagnosis by urethroscopy and radiological evaluation was localized urethral diverticular tumor. Pathological examination of the biopsy specimen revealed adenocarcinoma. The patient received two courses of intra-arterial and systemic chemotherapy using cisplatin, 5-fluorouracil and leucovorin, followed by radiation to the urethra. The tumor shrunk markedly after chemotherapy. The patient underwent total urethrectomy and vesicostomy. Two years after the operation, she had no evidence of recurrence. Adenocarcinoma of the female urethral diverticulum is rare and has been treated by surgery and/or radiation. The present case is the first case of it being treated by multimodality therapy including chemotherapy.

show abstract

“…Oral EMP in combination with etoposide is a treatment regimen for patients with hormone-refractory prostate cancer and thereby deserves further investigation [323] . Clinical evaluation of this drug and vinblastine in patients with hormone-refractory prostate cancer has also been reported [324] .…”

Section: Mapsmentioning

confidence: 97%

Microtubulin Binding Sites as Target for Developing Anticancer Agents

Islam¹,

Iskander²

2004

MRMC

132

View full text Add to dashboard Cite

Microtubules (MTs) play important and diverse roles in eukaryotic cells. Their function and biophysical properties have made alpha-and beta-tubulin, the main components of MTs, the subject of intense study. Interfering with normal MT dynamics, for example, by the addition of tubulin ligands, can cause the cell great distress and affect MT stability and functions, including mitosis, cell motion and intracellular organelle transport. It has been shown in the literature that tubulin is an important target molecule for developing anticancer drugs. Tubulin binding molecules have generated considerable interest after the successful introduction of the taxanes into clinical oncology and the widespread use of the vinca alkaloids vincristine and vinblastine. These compounds inhibit cell mitosis by binding to the protein tubulin in the mitotic spindle and preventing polymerization into the MTs. This mode of action is also shared with other natural agents eg colchicine and podophyllotoxin. However various tubulin isotypes have shown resistance to taxanes and other MT agents. Therefore, there is a strong need to design and develop new natural analogs as antimitotic agents to interact with tubulin at sites different from those of vinca alkaloids and taxanes. This minireview provides SAR on several classes of antimitotic agents reported in the literature. The structures and data given are essential to the scientists who are involved in drug design and development in the field of anticancer drugs.

show abstract

Intra‐arterial infusion of 5‐fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder*

Cited by 4 publications

References 11 publications

A Rare Case of Advanced Urethral Diverticular Adenocarcinoma and a Review of Treatment Modalities

A Rare Case of Advanced Urethral Diverticular Adenocarcinoma and a Review of Treatment Modalities

Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy

Microtubulin Binding Sites as Target for Developing Anticancer Agents

Contact Info

Product

Resources

About